What is your experience with the modified ramp-up of tarlatamab, where an extra 5 mg is given in the ramp-up phase before increasing to the full dose?

We have not attempted this approach and have had relatively little cytokine release syndrome (CRS) associated with the C1D8 10 mg dosing to suggest that a gentler step-up regimen is required. There are some reports that for patients with medullary thyroid cancer, a modified step-up dosing has been b...